Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.94% | 75.65% | 60.55% | 57.08% | 47.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.94% | 75.65% | 60.55% | 57.08% | 47.42% |
| Cost of Revenue | -5.62% | -7.82% | -12.17% | -10.42% | -5.64% |
| Gross Profit | 303.17% | 153.34% | 107.14% | 82.33% | 56.00% |
| SG&A Expenses | 9.13% | 3.38% | -0.54% | -0.32% | 6.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.16% | -2.02% | -6.25% | -5.29% | 0.56% |
| Operating Income | 46.03% | 36.26% | 32.00% | 26.52% | 14.67% |
| Income Before Tax | 55.86% | 45.61% | 14.78% | 6.55% | -4.14% |
| Income Tax Expenses | -127.25% | -109.52% | -46.19% | 19.27% | 1.42% |
| Earnings from Continuing Operations | 55.93% | 45.66% | 14.80% | 6.54% | -4.14% |
| Earnings from Discontinued Operations | -100.02% | -100.32% | -100.35% | -100.87% | 290.98% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.86% | -40.70% | -188.64% | -303.74% | 52.54% |
| EBIT | 46.03% | 36.26% | 32.00% | 26.52% | 14.67% |
| EBITDA | 56.18% | 42.64% | 37.13% | 30.85% | 18.66% |
| EPS Basic | -8.73% | -33.93% | -156.92% | -215.81% | 58.36% |
| Normalized Basic EPS | 49.19% | 37.52% | 34.87% | 33.19% | 26.30% |
| EPS Diluted | -8.73% | -33.93% | -156.92% | -215.81% | 58.36% |
| Normalized Diluted EPS | 49.19% | 37.52% | 34.87% | 33.19% | 26.30% |
| Average Basic Shares Outstanding | 10.01% | 6.81% | 6.25% | 8.50% | 12.85% |
| Average Diluted Shares Outstanding | 10.01% | 6.81% | 6.25% | 8.50% | 12.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |